Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | CASR | P41180 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21759173 | 0.93 | POLB (0.76) | POLBALDH1A1TSHRNPC1MAPT | |
| SCHEMBL6027881 | 0.90 | POLB (0.81) | POLBALDH1A1TSHRNPC1MAPT | |
| SCHEMBL13866493 | 0.90 | POLB (0.81) | POLBALDH1A1TSHRNPC1MAPT | |
| SCHEMBL21759172 | 0.89 | POLB (0.71) | POLBALDH1A1TSHRNPC1MAPT | |
| SCHEMBL6321886 | 0.87 | ALDH1A1 (0.63) | POLBALDH1A1TSHRNPC1MAPT | |
| SCHEMBL21759059 | 0.86 | POLB (0.67) | POLBALDH1A1TSHRNPC1MAPT | |
| SCHEMBL12122811 | 0.85 | POLB (0.63) | POLBALDH1A1TSHRNPC1MAPT | |
| Hydrochloric Acid SCHEMBL6320402 | 0.84 | ALDH1A1 (0.62) | POLBALDH1A1TSHRNPC1MAPT | |
| SCHEMBL20050081 | 0.82 | ABCB1 (0.67) | POLBALDH1A1TSHRMAPTMAPK1 | |
| SCHEMBL20050150 | 0.82 | POLB (0.62) | POLBALDH1A1TSHRNPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673853-B2 | Small molecule AMPK activators | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673853-B2 | Small molecule AMPK activators | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220153685-A1 | SMALL MOLECULE AMPK ACTIVATORS | THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS TECHNOLOGY TRANSFER PROGRAM (10P9TT) | 2022-05-19 | — | — | US | disclosed |
| US-11040935-B2 | Small molecule AMPK activators | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200062693-A1 | SMALL MOLECULE AMPK ACTIVATORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-02-27 | — | — | US | disclosed |
| US-7030110-B2 | Cyclic oxyguanidine pyrazinones as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060058291-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1303510-A2 | CYCLIC OXYGUANIDINE PYRAZINONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20030073702-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6476016-B2 | INHIBITING LOSS OF BLOOD PLATELETS, INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, INHIBITING FORMATION OF FIBRIN, INHIBITING THROMBUS FORMATION, AND INHIBITING EMBOLUS FORMATION | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020052357-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1189901-A1 | OXAZAHETEROCYCLES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2002006248-A2 | CYCLIC OXYGUANIDINE PYRAZINONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| US-6326492-B1 | ANTICOAGULANT | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-12-04 | — | — | US | disclosed |
| WO-2000073302-A1 | OXAZAHETEROCYCLES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673853-B2 | Small molecule AMPK activators | PRKAG1, PRKAG2, PRKAA1 | POLB 3111/4885ALDH1A1 2770/4885TSHR 3173/4885 |
| US-20020052357-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, SERPINE1, TFPI | POLB 2146/4885ALDH1A1 2762/4885TSHR 1195/4885 |
| US-20220153685-A1 | SMALL MOLECULE AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAA1 | POLB 3111/4885ALDH1A1 2770/4885TSHR 3173/4885 |
| US-11040935-B2 | Small molecule AMPK activators | PRKAG1, PRKAG2, PRKAA1 | POLB 3111/4885ALDH1A1 2770/4885TSHR 3173/4885 |
| US-20200062693-A1 | SMALL MOLECULE AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAA1 | POLB 3111/4885ALDH1A1 2770/4885TSHR 3173/4885 |
| US-20030073702-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, SERPINE1, TFPI | POLB 2146/4885ALDH1A1 2762/4885TSHR 1195/4885 |
| US-20060058291-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, TFPI, F12 | POLB 2062/4885ALDH1A1 3782/4885TSHR 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.